Clinical Trial Details

Trial ID: L0167
Source ID: NCT02854605
Associated Drug: GS-9674
Title: Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
Acronym: --
Status: Completed
Study Results: Has Results
Results: https://ClinicalTrials.gov/show/NCT02854605/results
Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: GS-9674|Drug: Placebo to match GS-9674
Outcome Measures: Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)|Overall Safety of GS-9674 as Assessed By Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
Sponsor/Collaborators: Gilead Sciences
Gender: All
Age: 18 Years to 75 Years ?? (Adult, Older Adult)
Phases: Phase 2
Enrollment: 140
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
Start Date: October 26, 2016
Completion Date: January 9, 2018
Results First Posted: January 29, 2019
Last Update Posted: January 29, 2019
Locations: Ruane Clinical Research Group Inc., Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Clinical Research Unit, Chicago, Illinois, United States|Crescent Clinical Research Center, LLC, Metairie, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Concorde Medical Group, PLLC, New York, New York, United States|Duke University Medical Center, Duke South Clinics, Durham, North Carolina, United States|Carolinas Center for Liver Disease/Carolinas HealthCare System, Durham, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research, PC, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Intermountain Liver Disease and Transplant Center, Murray, Utah, United States|Bon Secours St. Mary's Hospital of Richmond, Inc d/b/a Bon Secours Liver Institute of Virginia, Newport News, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|LMC Clinical Research Inc (Bayview), Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Liver Center, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|Princess Margaret Hospital, Kowloon, Hong Kong|The Chinese University of Hong Kong, Sha Tin, Hong Kong|Auckland Clinical Studies, Auckland, New Zealand|Universitatsspital Bern, Inselspital, Universitatsklinik fur Viszerale Chirurgie und Medizin, Hepatologie, Bern, Switzerland|Universitatsspital Zurich, Zurich, Switzerland|Addenbrooke's Hospital, Cambridge, United Kingdom
URL: https://ClinicalTrials.gov/show/NCT02854605

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D078 Cilofexor Chemical drug DB15168 FXR agonist Enhance lipid metabolism Under clinical trials Details